pone.0294743.s002.docx (30.55 kB)
Biobank participant questionnaire data.
journal contribution
posted on 2024-02-29, 18:22 authored by Emily J. Parker, Suzanne G. Orchard, Tom J. Gilbert, James J. Phung, Alice J. Owen, Trevor Lockett, Mark R. Nelson, Christopher M. Reid, Andrew M. Tonkin, Walter P. Abhayaratna, Peter Gibbs, John J. McNeil, Robyn L. WoodsTable reports the questions (abbreviated from actual) asked of participants at the time of biospecimen collections and the numbers (and percentage of total) of participants who recorded each answer. The options were “yes” or “no” or “unsure” with the latter numbers including those questions not answered. The differences in the questions at year 3 compared with baseline collections were mainly related to use of open-label aspirin and the ASPREE clinical trial medication.
(DOCX)
History
Usage metrics
Categories
Keywords
xlink "> aspirinmean participant ageextensive phenotypic informationlow dose aspirincontrolled prevention trialaustralian aspree participantsthree years aparthigh quality demographiccardiovascular disease eventsbiospecimens collected prior712 provided saliva4 million aliquotsaspree biobank houseshigh qualityaspree trialaspree biobankreducing eventsmultiple lowmajor diseaseaspree ),biospecimen biobankyear followwilling subsetvalidate diagnostictwo timepointsspecially designedrural areasrelated diseasespredictive biomarkersnitrogen vapournearly 100major bleedslogistical challengeslarge numbergenetic testingfuture researchfirst timepointdespite geographicalcollected annuallyclinical manifestationsclinical databarcoded cryotubes74 years7 years
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC